Online, CJC-1295 often gets one chart and one “schedule.”
In research talk, the first fork is usually different: with DAC vs without DAC (sometimes discussed alongside Mod GRF 1-29-style short-acting forms).
Plain English
CJC-1295 is studied as a GHRH-pathway research peptide (growth-hormone–releasing hormone related signaling).
DAC (Drug Affinity Complex) is a modification discussed because it can extend how long the molecule stays in circulation compared with shorter-acting analogs.
That half-life / duration difference is why frequency conversations in papers and reviews often split by form — not because one internet calendar fits every vial label.
Evidence labels (be honest)
- Mechanistic / pharmacology framing: GHRH-pathway signaling; DAC discussed for prolonged presence
- Human data: exists in limited clinical/research contexts for related GHRH analogs — not the same as “copy this forum schedule”
- Preclinical / early literature: used to explore GH-axis signaling; do not treat animal or early findings as a personal protocol
- Anecdotal / community charts: weakest evidence tier for timing claims
Important limitation
“With DAC” vs “without DAC” is an educational distinction about duration framing.
It is not personalized medical dosing advice. Published research context ≠ a recommendation to use any amount, route, or schedule.
Practical takeaway
When someone posts a CJC “timing chart,” ask:
- Which form are they even talking about (DAC vs non-DAC / short-acting)?
- Is the claim grounded in labeled evidence (human / preclinical / mechanistic / anecdote)?
- Are they mixing research protocol language with internet protocol language?
If the form isn’t specified, the timing claim is already fuzzy.
Discussion
When you see CJC timing advice online, do you weigh form + half-life explanations first — or community schedule charts — and why?